The development of artificial intelligence (AI) in the field of health represents a profound transformation in the way we prevent, diagnose and treat diseases. Thanks to its ability to analyze large volumes of clinical data, medical images and complex patterns, an AI solution makes it possible to detect health problems more accurately and quickly, support clinical decision making and personalize treatments according to the characteristics of each patient.
In this sense, HP has developed an innovative technological solution for mAbxience, a global biotechnology company dedicated to the development and manufacturing of biological products, focused on optimizing the production of biosimilar medicines through a digital twin of the biological process.
The project has been executed by the HP IA Lab team in León, within the framework of a strategic collaboration between both companies, and becomes a real example of how AI can generate a tangible impact on the quality, efficiency and access to treatments that improve the lives of thousands of people.
“This is a clear example of technology with a purpose: we use artificial intelligence not only to optimize processes, but also to help critical treatments reach earlier, better and to more people,” said Sergio Martínez, technical manager of the project at HP.
The solution developed by HP combines:
• A predictive model, which estimates in advance the amount of protein that will be obtained at the end of the production process.
• An optimizer, which proposes real-time adjustments to maximize the production of a biosimilar drug used in oncology and improve consistency between different batches.
• A cloud application, which allows the mAbxience technical team to easily interact with the prediction and simulation tools from the plant.
The global impact of AI on health
In recent years, artificial intelligence has become a key tool to transform the healthcare sector. From medical diagnosis to research into new treatments, AI technologies are accelerating processes, reducing costs and improving clinical outcomes. It represents a significant step forward towards more innovative, safe and patient-centred healthcare.
In this context, the project developed by HP represents a new line of application: the optimization of biopharmaceutical processes, allowing companies like mAbxience to produce in a more predictable way, with higher performance and less risk.
The development has been based on real production data, processed using advanced neural models, and has been integrated into an application that allows mAbxience technical teams to simulate, analyze and optimize each production batch.
“Artificial intelligence can unlock huge untapped potential for biomanufacturing optimization,” said Timo Liebig, chief innovation officer at mAbxience.
“Thanks to this collaboration with HP, we have successfully developed our first digital twin prototype, that is, integrated predictive models and optimization systems for our cell culture production processes, with the aim of enabling more efficient, more robust and even more controlled manufacturing campaigns. This project demonstrates how technological innovation can be directly translated into better patient access to essential biological therapies,” commented Iván Sánchez, R&D director at mAbxience.
This project is the first carried out under the framework agreement established between HP and mAbxience to apply artificial intelligence in different critical areas of the company. The solution, designed and validated in León, has the potential to be replicated in other plants and production processes in the future.
Beyond its technological innovation, this solution has transformative potential for all mAbxience partners, both biosimilar licensees and CDMO clients. By integrating AI into its manufacturing operations, mAbxience seeks to significantly optimize its development approach to biologics, improving operational efficiency and optimizing resource utilization.
AI developed by HP, in collaboration with mAbxience, optimizes the manufacturing process and speeds up the availability of treatments for cancer patients
This advancement will strengthen the company’s position as a trusted and cost-competitive global biomanufacturing partner, while helping to optimize patient access to safe, high-quality biologic medicines.
Additionally, this initiative aligns with HP’s vision of providing a comprehensive solution that drives innovation in biomanufacturing and enables its partners to adopt AI technologies more quickly and effectively. Thanks to this solution, mAbxience will be able to strengthen its production capacity and respond more quickly to the growing demand for biological therapies.
